Infectious Disease Treatment Market Research Report Information By Disease Type (Viral Diseases, Bacterial Diseases, Fungal Diseases, Parasitic Diseases and others), Treatment (Antibiotics, Antivirals, Antifungals, Anti-Parasitic and others), End User (Hospitals & Clinics, Ambulatory Care Centers and others) and Region (the Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2032

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL INFECTIOUS DISEASE TREATMENT MARKET, BY DISEASE TYPE

6.1. Overview

6.2. Viral Diseases

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

6.3. Bacterial Diseases

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

6.4. Fungal Diseases

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

6.5. Parasitic Diseases

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

6.6. Others

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

7. GLOBAL INFECTIOUS DISEASE TREATMENT MARKET, BY TREATMENT

7.1. Overview

7.2. Antibiotics

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

7.3. Antivirals

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

7.4. Antifungals

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

7.5. Anti-Parasitic

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

7.6. Others

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

8. GLOBAL INFECTIOUS DISEASE TREATMENT MARKET, BY END USER

8.1. Overview

8.2. Hospitals and Clinics

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

8.3. Ambulatory Care Centers

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

8.4. Others

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

9. GLOBAL INFECTIOUS DISEASE TREATMENT MARKET, BY REGION

9.1. Overview

9.2. Americas

9.2.1. North America

9.2.1.1. US

9.2.1.2. Canada

9.2.2. Latin America

9.3. Europe

9.3.1. Western Europe

9.3.1.1. Germany

9.3.1.2. France

9.3.1.3. Italy

9.3.1.4. Spain

9.3.1.5. UK

9.3.1.6. Rest of Western Europe

9.3.2. Eastern Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest of Asia-Pacific

9.5. Middle East & Africa

9.5.1. Middle East

9.5.2. Africa

10. COMPANY LANDSCAPE

10.1. Overview

10.2. Competitive Analysis

10.3. Market Share Analysis

10.4. Major Growth Strategy in the Global Infectious Disease Treatment Market

10.5. Competitive Benchmarking

10.6. Leading Players in Terms of the Number of Developments in the Global Infectious Disease Treatment Market

10.7. Key Developments and Growth Strategies

10.7.1. Product Launch/Service Deployment

10.7.2. Mergers and Acquisitions

10.7.3. Joint Ventures

10.8. Major Players Financial Matrix & Market Ratio

10.8.1. Sales & Operating Income 2022

10.8.2. Major Players R&D Expenditure 2022

10.9. Major Players Capital Market Ratio

11. COMPANY PROFILES

11.1. F. Hoffmann-La Roche Ltd

11.1.1. Company Overview

11.1.2. Product Overview

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Pfizer Inc.

11.2.1. Company Overview

11.2.2. Product Overview

11.2.3. Financial Overview

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. Janssen Global Services, LLC

11.3.1. Company Overview

11.3.2. Product Overview

11.3.3. Financial Overview

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. Sanofi

11.4.1. Company Overview

11.4.2. Product Overview

11.4.3. Financial Overview

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. GlaxoSmithKline PLC

11.5.1. Company Overview

11.5.2. Product Overview

11.5.3. Financial Overview

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. Novartis AG

11.6.1. Company Overview

11.6.2. Product Overview

11.6.3. Financial Overview

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. Bristol-Myers Squibb Company

11.7.1. Company Overview

11.7.2. Product Overview

11.7.3. Financial Overview

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. Bayer AG

11.8.1. Company Overview

11.8.2. Product Overview

11.8.3. Financial Overview

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. Eli Lilly and Company

11.9.1. Company Overview

11.9.2. Product Overview

11.9.3. Financial Overview

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. Astellas Pharma Inc.

11.10.1. Company Overview

11.10.2. Product Overview

11.10.3. Financial Overview

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

11.11. Merck & Co., Inc.

11.11.1. Company Overview

11.11.2. Product Overview

11.11.3. Financial Overview

11.11.4. Key Developments

11.11.5. SWOT Analysis

11.11.6. Key Strategies

11.12. Aurobindo Pharma

11.12.1. Company Overview

11.12.2. Product Overview

11.12.3. Financial Overview

11.12.4. Key Developments

11.12.5. SWOT Analysis

11.12.6. Key Strategies

11.13. Dr. Reddy’s Laboratories

11.13.1. Company Overview

11.13.2. Product Overview

11.13.3. Financial Overview

11.13.4. Key Developments

11.13.5. SWOT Analysis

11.13.6. Key Strategies

11.14. Cipla Inc.

11.14.1. Company Overview

11.14.2. Product Overview

11.14.3. Financial Overview

11.14.4. Key Developments

11.14.5. SWOT Analysis

11.14.6. Key Strategies

11.15. Alkem Labs

11.15.1. Company Overview

11.15.2. Product Overview

11.15.3. Financial Overview

11.15.4. Key Developments

11.15.5. SWOT Analysis

11.15.6. Key Strategies

11.16. AbbVie Inc.

11.16.1. Company Overview

11.16.2. Product Overview

11.16.3. Financial Overview

11.16.4. Key Developments

11.16.5. SWOT Analysis

11.16.6. Key Strategies

11.17. Others

12. APPENDIX

12.1. References

12.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL INFECTIOUS DISEASE TREATMENT MARKET SYNOPSIS, 2022–2030

TABLE 2 GLOBAL INFECTIOUS DISEASE TREATMENT MARKET ESTIMATES & FORECAST, 2022–2030 (USD Billion)

TABLE 3 GLOBAL INFECTIOUS DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2022–2030 (USD Billion)

TABLE 4 GLOBAL INFECTIOUS DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion)

TABLE 5 GLOBAL INFECTIOUS DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion)

TABLE 6 GLOBAL INFECTIOUS DISEASE TREATMENT MARKET, BY REGION, 2022–2030 (USD Billion)

TABLE 7 NORTH AMERICA: INFECTIOUS DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2022–2030 (USD Billion)

TABLE 8 NORTH AMERICA: INFECTIOUS DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion)

TABLE 9 NORTH AMERICA: INFECTIOUS DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion)

TABLE 10 US: INFECTIOUS DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2022–2030 (USD Billion)

TABLE 11 US: INFECTIOUS DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion)

TABLE 12 US: INFECTIOUS DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion)

TABLE 13 CANADA: INFECTIOUS DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2022–2030 (USD Billion)

TABLE 14 CANADA: INFECTIOUS DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion)

TABLE 15 CANADA: INFECTIOUS DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion)

TABLE 16 LATIN AMERICA: INFECTIOUS DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2022–2030 (USD Billion)

TABLE 17 LATIN AMERICA: INFECTIOUS DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion)

TABLE 18 LATIN AMERICA: INFECTIOUS DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion)

TABLE 19 EUROPE: INFECTIOUS DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2022–2030 (USD Billion)

TABLE 20 EUROPE: INFECTIOUS DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion)

TABLE 21 EUROPE: INFECTIOUS DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion)

TABLE 22 WESTERN EUROPE: INFECTIOUS DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2022–2030 (USD Billion)

TABLE 23 WESTERN EUROPE: INFECTIOUS DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion)

TABLE 24 WESTERN EUROPE: INFECTIOUS DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion)

TABLE 25 EASTERN EUROPE: INFECTIOUS DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2022–2030 (USD Billion)

TABLE 26 EASTERN EUROPE: INFECTIOUS DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion)

TABLE 27 EASTERN EUROPE: INFECTIOUS DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion)

TABLE 28 ASIA-PACIFIC: INFECTIOUS DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2022–2030 (USD Billion)

TABLE 29 ASIA-PACIFIC: INFECTIOUS DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion)

TABLE 30 ASIA-PACIFIC: INFECTIOUS DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion)

TABLE 31 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2022–2030 (USD Billion)

TABLE 32 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE TREATMENT MARKET, BY TREATMENT, 2022–2030 (USD Billion)

TABLE 33 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE TREATMENT MARKET, BY END USER, 2022–2030 (USD Billion)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL INFECTIOUS DISEASE TREATMENT MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL INFECTIOUS DISEASE TREATMENT MARKET

FIGURE 4 GLOBAL INFECTIOUS DISEASE TREATMENT MARKET SHARE, BY DISEASE TYPE, 2022 (%)

FIGURE 5 GLOBAL INFECTIOUS DISEASE TREATMENT MARKET SHARE, BY TREATMENT TYPE, 2022 (%)

FIGURE 6 GLOBAL INFECTIOUS DISEASE TREATMENT MARKET SHARE, BY END USER, 2022 (%)

FIGURE 7 GLOBAL INFECTIOUS DISEASE TREATMENT MARKET SHARE, BY REGION, 2022 (%)

FIGURE 7 AMERICAS: INFECTIOUS DISEASE TREATMENT MARKET SHARE BY REGION, 2022 (%)

FIGURE 8 NORTH AMERICA: INFECTIOUS DISEASE TREATMENT MARKET SHARE, BY COUNTRY, 2022 (%)

FIGURE 9 EUROPE: INFECTIOUS DISEASE TREATMENT MARKET SHARE, BY REGION, 2022 (%)

FIGURE 10 WESTERN EUROPE: INFECTIOUS DISEASE TREATMENT MARKET SHARE, BY COUNTRY, 2022 (%)

FIGURE 11 ASIA-PACIFIC: INFECTIOUS DISEASE TREATMENT MARKET SHARE, BY COUNTRY, 2022 (%)

FIGURE 12 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE TREATMENT MARKET SHARE, BY COUNTRY, 2022 (%)

FIGURE 13 GLOBAL INFECTIOUS DISEASE TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2022 (%)

FIGURE 14 F. HOFFMANN-LA ROCHE LTD.: KEY FINANCIALS

FIGURE 15 F. HOFFMANN-LA ROCHE LTD: SEGMENTAL REVENUE

FIGURE 16 F. HOFFMANN-LA ROCHE LTD: REGIONAL REVENUE

FIGURE 17 PFIZER INC.: KEY FINANCIALS

FIGURE 18 PFIZER INC.: SEGMENTAL REVENUE

FIGURE 19 PFIZER INC.: REGIONAL REVENUE

FIGURE 20 JANSSEN GLOBAL SERVICES, LLC: KEY FINANCIALS

FIGURE 21 JANSSEN GLOBAL SERVICES, LLC: SEGMENTAL REVENUE

FIGURE 22 JANSSEN GLOBAL SERVICES, LLC: REGIONAL REVENUE

FIGURE 23 SANOFI: KEY FINANCIALS

FIGURE 24 SANOFI: SEGMENTAL REVENUE

FIGURE 25 SANOFI: REGIONAL REVENUE

FIGURE 26 GLAXOSMITHKLINE PLC: KEY FINANCIALS

FIGURE 27 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE

FIGURE 28 GLAXOSMITHKLINE PLC: REGIONAL REVENUE

FIGURE 29 NOVARTIS AG: KEY FINANCIALS

FIGURE 30 NOVARTIS AG: SEGMENTAL REVENUE

FIGURE 31 NOVARTIS AG: REGIONAL REVENUE

FIGURE 32 BRISTOL-MYERS SQUIBB COMPANY: KEY FINANCIALS

FIGURE 33 BRISTOL-MYERS SQUIBB COMPANY: SEGMENTAL REVENUE

FIGURE 34 BRISTOL-MYERS SQUIBB COMPANY: REGIONAL REVENUE

FIGURE 35 BAYER AG.: KEY FINANCIALS

FIGURE 36 BAYER AG.: SEGMENTAL REVENUE

FIGURE 37 BAYER AG.: REGIONAL REVENUE

FIGURE 38 ELI LILLY AND COMPANY: KEY FINANCIALS

FIGURE 39 ELI LILLY AND COMPANY: SEGMENTAL REVENUE

FIGURE 40 ELI LILLY AND COMPANY: REGIONAL REVENUE

FIGURE 41 ASTELLAS PHARMA INC.: KEY FINANCIALS

FIGURE 42 ASTELLAS PHARMA INC.: SEGMENTAL REVENUE

FIGURE 43 ASTELLAS PHARMA INC.: REGIONAL REVENUE

FIGURE 44 MERCK & CO., INC.: KEY FINANCIALS

FIGURE 45 MERCK & CO., INC.: SEGMENTAL REVENUE

FIGURE 46 MERCK & CO., INC.: REGIONAL REVENUE

FIGURE 47 AUROBINDO PHARMA: KEY FINANCIALS

FIGURE 48 AUROBINDO PHARMA: SEGMENTAL REVENUE

FIGURE 49 AUROBINDO PHARMA: REGIONAL REVENUE

FIGURE 50 DR. REDDY’S LABORATORIES: KEY FINANCIALS

FIGURE 51 DR. REDDY’S LABORATORIES: SEGMENTAL REVENUE

FIGURE 52 DR. REDDY’S LABORATORIES: REGIONAL REVENUE

FIGURE 53 CIPLA INC.: KEY FINANCIALS

FIGURE 54 CIPLA INC.: SEGMENTAL REVENUE

FIGURE 55 CIPLA INC.: REGIONAL REVENUE

FIGURE 56 ALKEM LABS: KEY FINANCIALS

FIGURE 57 ALKEM LABS: SEGMENTAL REVENUE

FIGURE 58 ALKEM LABS: REGIONAL REVENUE

FIGURE 59 ABBVIE INC.: KEY FINANCIALS

FIGURE 60 ABBVIE INC.: SEGMENTAL REVENUE

FIGURE 61 ABBVIE INC.: REGIONAL REVENUE